Research is being conducted on the outcomes of patients who have experienced myopathy related to immune checkpoint inhibitors. The studies are examining various aspects, including incidence, clinical characteristics, and management strategies for immune-related adverse events, such as myocarditis and neuromuscular disorders. The findings appear to cover a range of topics, from diagnostic challenges to the exploration of underlying mechanisms and potential treatment options.